Financhill
Back

Elite Pharmaceuticals Quote, Financials, Valuation and Earnings

U.S. Government Report Alert Tuesday

Discover the Secret Loophole
Sell
50

ELTP
Elite Pharmaceuticals

Last Price:
0.52
Seasonality Move:
11.78%

7 Day Trial

ALL ACCESS PASS

$ 7

Yours Free! Top SIX AI Dividend Stocks Right Now

NO CREDIT CARD REQUIRED!

Elite Pharmaceuticals Price Quote

$0.52
+0.01 (+2%)
(Updated: November 7, 2024 at 5:13 AM ET)

Elite Pharmaceuticals Key Stats

Sell
50
Elite Pharmaceuticals (ELTP) is a Sell

Day range:
$0.48 - $0.53
52-week range:
$0.10 - $0.75
Dividend yield:
0%
P/E ratio:
25.49
P/S ratio:
7.97
P/B ratio:
9.35%

Volume:
1.6M
Avg. volume:
3.9M
1-year change:
335.33%
Market cap:
$544.6M
Revenue:
$56.6M
EPS:
$0.01

How Much Does Elite Pharmaceuticals Make?

Is Elite Pharmaceuticals Growing As A Company?

  • What Is Elite Pharmaceuticals's Growth Rate Quarterly?
    Quarterly YoY revenue growth is 1.09%
  • What Is Elite Pharmaceuticals's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is -0.49%

Elite Pharmaceuticals Stock Price Performance

What Is Elite Pharmaceuticals 52-Week High & Low?

Elite Pharmaceuticals Price To Free Cash Flow

Is It Risky To Buy Elite Pharmaceuticals?

Is Elite Pharmaceuticals Cash Flow Positive?

  • What Is ELTP Cash Flow From Operations?
    Cash flow from operations (TTM) is $2.6M
  • What Is Elite Pharmaceuticals’s Cash Flow From Financing?
    Cash flow from financing (TTM) is -$746.5K
  • What Is Elite Pharmaceuticals’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$2.5M

Elite Pharmaceuticals Return On Invested Capital

  • Is Management Doing A Good Job?
    ELTP return on invested capital is 35.5%
  • What Is Elite Pharmaceuticals Return On Assets?
    ROA measures how assets are converting to revenues and is 26.94%
  • What Is ELTP Return On Equity?
    ROE is a measure of profitability and is 41.23%

Elite Pharmaceuticals Earnings Date & Stock Price

Elite Pharmaceuticals Competitors

Elite Pharmaceuticals Dividend Yield

Elite Pharmaceuticals Analyst Estimates

YoY Growth Past Surprise
EPS: -49.16% 0%
Revenue: 109.39% 0%

Analyst Recommendations

Buy Recommendations: 1
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 4.00
Upside from Last Price: 676.7%

Major Shareholders

  • How many ELTP shares are owned by institutional investors?
    0 ELTP shares are owned by institutional investors
  • How many ELTP shares are owned by insiders?
    0 ELTP shares are owned by insiders